Bajaj Healthcare schedules board meeting on 20 July to approve Q1 FY2026 un‑audited results

What Bajaj Healthcare announced

Bajaj Healthcare Ltd (BSE: 539872) informed the Bombay Stock Exchange that its Board of Directors will convene on 20 July 2026. The agenda includes the consideration and approval of the unaudited financial results for the quarter ended 30 June 2026. The notice was submitted on 14 July 2026.

Board meeting details

• Date of meeting: 20 July 2026
• Time & venue: Not disclosed in the filing; standard practice is to hold the meeting at the company’s registered office.
• Agenda item: Review and approval of unaudited Q1 FY2026 financial statements.
• Filing timestamp: 2026‑07‑14T07:19:02Z (BSE submission).

The filing does not provide any quantitative data such as revenue, profit, or cash flow figures for the quarter. It merely serves as a regulatory notice that the board will discuss the results before they are formally audited and possibly released to shareholders.

Un‑audited financial results – what is known

The term un‑audited indicates that the numbers presented to the board have not yet undergone independent verification by auditors. Companies typically circulate these statements internally to obtain board approval, after which the audited version is filed with the stock exchanges. No specific financial metrics are disclosed in the current notice, so investors cannot assess performance from this filing alone.

Key facts at a glance

Why this matters for investors

The notice is a routine compliance filing required under SEBI (Listing Obligations) regulations. It signals that the company is progressing towards finalising its quarterly results. While no performance data is available yet, the board’s approval is a prerequisite for the subsequent audited filing, which will provide the detailed financial picture investors rely on for valuation and performance assessment.

Conclusion

Bajaj Healthcare has formally announced a board meeting on 20 July 2026 to approve its unaudited financial results for the quarter ended 30 June 2026. The filing contains no quantitative results, serving only as a procedural update. Investors should await the audited results, which are expected to be released after board approval and auditor sign‑off.